POST Online Media Lite Edition



 

Boehringer Ingelheim invests $57 million in Athens, Georgia

Christian Fernsby |
Boehringer Ingelheim will expand its Animal Health Global Innovation center in Athens, Georgia.

Article continues below




The $57 million investment will increase laboratory space and bring additional research and development capabilities and activities, including 55 new positions, to the site.

As a world-leading, research-driven pharmaceutical company, Germany-based Boehringer Ingelheim focuses on three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company manufactures well-respected and widely used vaccines, parasite-control products, and therapeutics for pets, horses, and livestock.

Construction began recently on a new 63,000-square-foot facility, located at 1730 Olympic Drive in Athens, that will connect two existing buildings currently housing laboratory and administrative space, along with a 5,000-square-foot expansion and partial renovation of existing Global Innovation facilities in Athens.

The new facility is slated to be complete in spring 2024. When complete, the expansion will bring Boehringer Ingelheim’s Global Innovation footprint in Athens to nearly 115,000 square feet and accommodate an additional 55 research and development positions at the site.

The new building and expansion will feature significant use of natural light in offices, laboratories, and collaboration spaces, with floor to ceiling windows in many areas. Construction debris will be segregated to facilitate recycling or disposal as appropriate.

There are more than 2,200 clinical trials recruiting or underway in Georgia. From 2014 through 2017, there were 547 patents awarded to applicants from Georgia for drugs and pharmaceuticals. In 2021, Georgia exported $3.2 billion in immunological products and $1.9 billion in medical devices and pharmaceuticals. â– 


What to read next

Boehringer Ingelheim to sell 40 million ordinary shares in Hikma
EC clears acquisition of Boehringer Ingelheim's business by Sanofi
Boehringer Ingelheim to sell 5 products to continue with $13.5bn Sanofi deal